Your browser doesn't support javascript.
loading
Evidence of a dual mechanism of action underlying the anti-proliferative and cytotoxic effects of ammonium-alkyloxy-stilbene-based α7- and α9-nicotinic ligands on glioblastoma cells.
Pucci, Susanna; Bolchi, Cristiano; Bavo, Francesco; Pallavicini, Marco; De Palma, Clara; Renzi, Massimiliano; Fucile, Sergio; Benfante, Roberta; Di Lascio, Simona; Lattuada, Donatella; Bessereau, Jean-Louis; D'Alessandro, Manuela; Risson, Valerie; Zoli, Michele; Clementi, Francesco; Gotti, Cecilia.
Afiliación
  • Pucci S; CNR, Institute of Neuroscience, Milan, Italy; NeuroMi Milan Center for Neuroscience University of Milano Bicocca,Italy.
  • Bolchi C; Dipartimento di Scienze Farmaceutiche, Università degli Studi di Milano, 20129 Milano, Italy.
  • Bavo F; Dipartimento di Scienze Farmaceutiche, Università degli Studi di Milano, 20129 Milano, Italy.
  • Pallavicini M; Dipartimento di Scienze Farmaceutiche, Università degli Studi di Milano, 20129 Milano, Italy.
  • De Palma C; Department of Medical Biotechnology and Translational Medicine, Università degli Studi di Milano, 20129 Milan, Italy.
  • Renzi M; Dipartimento di Fisiologia e Farmacologia, Sapienza Università di Roma, 00185 Roma, Italy.
  • Fucile S; Dipartimento di Fisiologia e Farmacologia, Sapienza Università di Roma, 00185 Roma, Italy; I.R.C.C.S. Neuromed, Via Atinese 18, 86077 Pozzilli, Italy.
  • Benfante R; CNR, Institute of Neuroscience, Milan, Italy; NeuroMi Milan Center for Neuroscience University of Milano Bicocca,Italy; Department of Medical Biotechnology and Translational Medicine, Università degli Studi di Milano, 20129 Milan, Italy.
  • Di Lascio S; Department of Medical Biotechnology and Translational Medicine, Università degli Studi di Milano, 20129 Milan, Italy.
  • Lattuada D; Department of Medical Biotechnology and Translational Medicine, Università degli Studi di Milano, 20129 Milan, Italy.
  • Bessereau JL; Univ Lyon, Université Claude Bernard Lyon 1, CNRS UMR 5310, INSERM U 1217, Institut NeuroMyoGène, Lyon, France.
  • D'Alessandro M; Univ Lyon, Université Claude Bernard Lyon 1, CNRS UMR 5310, INSERM U 1217, Institut NeuroMyoGène, Lyon, France.
  • Risson V; Univ Lyon, Université Claude Bernard Lyon 1, CNRS UMR 5310, INSERM U 1217, Institut NeuroMyoGène, Lyon, France.
  • Zoli M; Department of Biomedical, Metabolic and Neural Sciences, Center for Neuroscience and Neurotechnology (CfNN), University of Modena and Reggio Emilia, 41125 Modena, Italy.
  • Clementi F; CNR, Institute of Neuroscience, Milan, Italy; NeuroMi Milan Center for Neuroscience University of Milano Bicocca,Italy; Department of Medical Biotechnology and Translational Medicine, Università degli Studi di Milano, 20129 Milan, Italy.
  • Gotti C; CNR, Institute of Neuroscience, Milan, Italy; NeuroMi Milan Center for Neuroscience University of Milano Bicocca,Italy; Department of Medical Biotechnology and Translational Medicine, Università degli Studi di Milano, 20129 Milan, Italy. Electronic address: cecila.gotti@in.cnr.it.
Pharmacol Res ; 175: 105959, 2022 01.
Article en En | MEDLINE | ID: mdl-34756924
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Estilbenos / Neoplasias Encefálicas / Glioblastoma / Compuestos de Amonio / Antineoplásicos Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Año: 2022 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Estilbenos / Neoplasias Encefálicas / Glioblastoma / Compuestos de Amonio / Antineoplásicos Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Año: 2022 Tipo del documento: Article